Patrick Baeuerle Ph.D Overview
- Company
- Cullinan Therape...
- Primary Position
-
Chief Scientific...
- Primary Industry
-
Healthcare
- Active Board Seats
-
1
- Med. Deal Size
-
Patrick Baeuerle Ph.D General Information
Biography
Dr. Patrick Baeuerle is a Co-Founder and serves as a Board Member at TCR2 Therapeutics. He serves as a Medical And Scientific Advisory Board Member at MPM BioImpact. He is a Co-Founder of Crossbow Therapeutics. He previously served as a Board Member at Maverick Therapeutics. Dr. Baeuerle is also a Co-Founder and serves as Acting Chief Scientific Officer at Cullinan Oncology. He serves as a Board Member of Harpoon Therapeutics. He served as a Clinical and Scientific Advisor at Amphivena Therapeutics. He is also a Co-Founder and serves as Scientific Advisor at iOmx Therapeutics. He is also a Co-Founder of Aktis Oncology. He joined MPM in 2015 and has since co-founded MPM oncology start-ups: Harpoon Therapeutics, Inc., TCR Therapeutics, and Cullinan Pharmaceuticals LLC. Previously, he was responsible for the development of the BiTE antibody Blincyto, which was approved in 2014 within three months of submission by the U.S. FDA for the treatment of relapsed/refractory acute lymphoblastic leukemia. He also spearheaded the BiTE technology, the industry's leading T-cell-engaging bispecific antibody platform. Prior to joining MPM, Dr. Baeuerle served as Vice President, Research, and General Manager of Amgen Research Munich GmbH, where he oversaw translational sciences of BiTE antibodies. From 1998 to 2012, he served as Chief Scientific Officer for Micromet, Inc., and earlier headed small molecule drug discovery at Tularik, Inc., a publicly traded biotechnology company also acquired by Amgen (AMGN). From 1996-1998, he served as Professor and Chairman of Biochemistry and Molecular Biochemistry at the Medical Faculty of Freiburg University, Germany, where he did groundbreaking research on transcription factor NF-kappaB. Dr. Baeuerle has published more than 238 PubMed-listed papers that have been cited more than 64,000 times to date. He has a Hirsh index of 119 and was rated Germany's most frequently cited biomedical scientist of the decade (1990-1999) and among the top 50 worldwide (1990 to 1997). He holds a Ph.D. in biology from the University of Munich and performed post-doctoral research with Dr. David Baltimore at the Whitehead Institute at the Massachusetts Institute of Technology. He is also an Honorary Professor of Immunology of the Medical Faculty at Munich University.
Contact Information
Address
- Fraunhoferstrasse 13
- Martinsried
- 82152 Munich
- Germany
Patrick Baeuerle Ph.D Positions (3)
Firm name | Firm type | Title | Location | Industry | Since |
---|---|---|---|---|---|
Aktis Oncology | Company | Co-Founder & Advisor | Boston, MA | Drug Discovery | |
Crossbow Therapeutics | Company | Co-Founder | Cambridge, MA | Biotechnology | |
iOmx Therapeutics | Company | Co-Founder & Scientific Advisor | Munich, Germany | Drug Discovery |
Patrick Baeuerle Ph.D Board Seats (1)
Company | Industry | Ownership Status | Financing Status | Location | Since |
---|---|---|---|---|---|
Werewolf Therapeutics | Drug Discovery | Publicly Held | Formerly VC-backed | Cambridge, MA |
Patrick Baeuerle Ph.D Lead Partner on Deals (1)
Patrick Baeuerle Ph.D has been the lead partner on 1 deal. Their latest deal was with Cullinan Therapeutics, a drug discovery company. The deal was made for on 03-Oct-2017.
Company | Deal Date | Deal Type | Deal Size | Deal Status | Industry | Location |
---|---|---|---|---|---|---|
Cullinan Therapeutics | 03-Oct-2017 | Early Stage VC (Series A) | Completed | Drug Discovery | Cambridge, MA |
Patrick Baeuerle Ph.D Network (62)
Board Members (39)
Name | Company | Representing | Location | From |
---|---|---|---|---|
Michael Sherman | Werewolf Therapeutics | Self | Cambridge, MA | |
Derek DiRocco Ph.D | Werewolf Therapeutics | Self | Cambridge, MA | |
Maverick Therapeutics | Maverick Therapeutics | Brisbane, CA | ||
TCR2 Therapeutics | Self | Cambridge, MA | ||
Werewolf Therapeutics | Deerfield Management | Cambridge, MA |
Portfolio Executives (16)
Name | Company | Role | Deal date | Location |
---|---|---|---|---|
Mary Fenton | Cullinan Therapeutics | Chief Financial Officer | 03-Oct-2017 | Cambridge, MA |
Nadim Ahmed | Cullinan Therapeutics | President, Chief Executive Officer & Board Member | 03-Oct-2017 | Cambridge, MA |
Cullinan Therapeutics | Chief Business Officer | 03-Oct-2017 | Cambridge, MA | |
Cullinan Therapeutics | Secretary, Administration & Chief Legal Officer, Legal | 03-Oct-2017 | Cambridge, MA | |
Cullinan Therapeutics | Co-Founder | 03-Oct-2017 | Cambridge, MA |
Fund Team Members (7)
Name | Investor | Fund | Fund Location |
---|---|---|---|
Bard Geesaman Ph.D | UBS Group | UBS Oncology Impact Fund | Zurich, Switzerland |
Bard Geesaman Ph.D | MPM BioImpact | UBS Oncology Impact Fund | Boston, MA |
UBS Group | Zurich, Switzerland | ||
MPM BioImpact | Boston, MA | ||
UBS Group | Zurich, Switzerland |
Patrick Baeuerle Ph.D Affiliated Funds (1)
Fund | Investor | Fund Type | Status | Vintage | Size | Dry Powder | IRR | IRR Quartile |
---|---|---|---|---|---|---|---|---|
UBS Oncology Impact Fund | UBS Group | Venture - General | Closed | 2016 |
Patrick Baeuerle Ph.D Advisory Roles (1)
Firm name | Firm type | Title | Location | Industry | Since |
---|---|---|---|---|---|
MPM BioImpact | Investor | Medical And Scientific Advisory Board Member | Boston, MA | Venture Capital |
Patrick Baeuerle Ph.D FAQs
-
Who is Patrick Baeuerle Ph.D?
Dr. Patrick Baeuerle is a Co-Founder and serves as a Board Member at TCR2 Therapeutics.
-
How much does Patrick Baeuerle Ph.D typically invest?
Patrick Baeuerle Ph.D's median deal size is
. -
What is Patrick Baeuerle Ph.D’s main position?
Patrick Baeuerle Ph.D’s primary position is Chief Scientific Officer.
-
What are the contact details for Patrick Baeuerle Ph.D?
Patrick Baeuerle Ph.D’s email address is pb
and his phone number is +49 089 . -
How many active board seats does Patrick Baeuerle Ph.D hold?
Patrick Baeuerle Ph.D holds a board seat in Werewolf Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »